Some stocks are lagging the market for good reasons -- because their businesses look shaky and their prospects uncertain.

A new technology for management of diabetes is cost-effective for patients in the US with type 1 diabetes compared with traditional treatments.

Tandem Diabetes Care (TNDM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings ...

Fintel reports that on April 10, 2025, Mizuho initiated coverage of Tandem Diabetes Care (NasdaqGM:TNDM) with a Neutral ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $35.11, a high ...

Mizuho initiated coverage of Tandem Diabetes (TNDM) with a Neutral rating and $20 price target The firm’s neutral stance reflects both the ...

The doctors say barriers continue to prevent access to AID, including costs. Such barriers exemplify “the implicit ...

The Guam Memorial Hospital Authority said its acquisition of its first-ever intra-aortic balloon pump is a significant advancement that will transform cardiac care on the island. The state-of-the ...

A free event focused on diabetes care, technology, and research will take place on April 10 at the Legacy Centre from 5:30 ...

At the recent ATTD 2025 meeting, participants discussed recent progress and remaining challenges in developing a fully closed ...

A landmark international study involving patients and researchers at St. Joseph’s Health Care London shows automated insulin ...

The global disposable insulin-delivery device market is projected to experience robust growth over the next decade, according to recent industry insights. Valued at USD 14,585.6 million in 2022, the ...